re: #344 Decatur Deb

This is the core of the problem, which is touched further up the thread. If the purpose is to develop a preventive, preventing infection in the young healthy sample does the job. If it fails in that sample, the consequences are bad enough, but far less deadly. Nothing much is learned by failing on a sample we know is more brittle.

We will learn more from helping someone in a high risk group gain immunity than a healthy person. And we will learn something if the vaccine works on a healthy group and fails on a more brittle person. The only time we wouldn’t learn something is if it fails in all groups.